Rung 4 · Strong
Durvalumab after chemoradiation for limited-stage small cell lung cancer
Longer survival in a large randomized trial.
TreatmentWith your doctor
What studies found
In ADRIATIC (730 patients), durvalumab after chemoradiation gave median survival of 55.9 months versus 33.4 months with placebo. The FDA approved it on 4 December 2024.
The catch
For limited-stage disease after chemoradiation only.
What to do
If you have limited-stage small cell lung cancer, ask about durvalumab after chemoradiation.
Sources
Rung 4 of 5, Strong: At least one large randomized trial, or very large consistent studies, on this exact question. How we score
To take it to your doctor, print this page.
Step by step
For the whole picture, from prevention and screening to treatment and life after, see the lung cancer page.
Related
- Tumor gene testing before lung cancer treatmentRung 5 · EstablishedWith your doctorRung 5 · EstablishedTreatmentWith your doctor
- Amivantamab plus lazertinib for advanced EGFR lung cancerRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Immunotherapy around surgery for non-small cell lung cancerRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Targeted pills after surgery or chemoradiation for EGFR or ALK lung cancerRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Tarlatamab for small cell lung cancer that returns after chemotherapyRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor